Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.30M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -11.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 12.34M shares, increasing 7.43% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 954.08K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.71.